On June 17, Insilico Medicine rose 5.17% in regular trading, trading at 34.62 HKD/share, with turnover of approximately 13.92 million HKD.

On the news front, the company announced that ISM8969, co-developed with Shenzhen Hengtai Biotech, has achieved its first clinical milestone by completing first-in-human dosing in a Phase I study. ISM8969 is an oral small molecule NLRP3 inflammasome inhibitor with potential best-in-class profile and blood-brain barrier penetration capability, intended for treating chronic neuroinflammation and central nervous system diseases. Under the collaboration agreement, both parties hold 50% global rights, and Insilico Medicine is entitled to receive up to 66 million USD in upfront and milestone payments.

The clinical advancement follows last week's inclusion in the CSI Index series and upcoming FTSE Global Equity Index inclusion on June 22. However, approximately 453 million restricted shares representing 81.25% of total equity are set to unlock on June 29, with potential selling pressure remaining a key overhang.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)